A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

NCT04712643 PHASE3 ACTIVE_NOT_RECRUITING

This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	342
Start date	Fri Mar 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Feb 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatocellular Carcinoma

Interventions

• Atezolizumab
• Becavizumab
• Transarterial chemoembolization (TACE)

Countries

China, Japan